A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

作者： Wendy E. Heywood*1, Anna Baud*1, Emily Bliss1, Ernestas Sirka1, Jonathan M. Schott2, Henrik Zetterberg3, Daniela Galimberti4, Neil J. Sebire5, Kevin Mills1 1Centre for Translational Omics, Genetics and Genomic Medicine Deptartment, Great Ormond Street Institute of Child Health,University College London, 2Dementia Research Centre, Institute of Neurology,University College London, 3Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy,University of Gothenburg, 4Neurology Unit, Department of Pathophysiology and Transplantation,University of Milan, 5Great Ormond Street Hospital for Children,University College London

简介：

Overview

This article presents a high-throughput, multiplex, and targeted proteomic assay for cerebrospinal fluid (CSF) that has potential clinical applications. The assay quantifies biomarkers associated with neurodegeneration, including apolipoprotein E variants.

Key Study Components

Area of Science

• Neuroscience
• Proteomics
• Clinical Diagnostics

Background

• Cerebrospinal fluid (CSF) is a valuable source for biomarker discovery.
• Neurodegenerative diseases require effective diagnostic tools.
• Current methods may not measure all relevant biomarkers.
• High-throughput assays can enhance diagnostic capabilities.

Purpose of Study

• To develop a rapid and cost-effective assay for quantifying multiple biomarkers in CSF.
• To assess the potential of these biomarkers for diagnosis and treatment monitoring.
• To differentiate between various neurodegenerative diseases.

Methods Used

• High-throughput multiplex proteomic assay development.
• Quantitation of apolipoprotein E variants (E2, E3, E4).
• Sample preparation designed for simplicity and speed.
• Application of the assay in clinical settings for neurodegeneration.

Main Results

• The assay successfully quantifies multiple biomarkers in CSF.
• It allows for the measurement of previously unmeasurable biomarkers.
• Demonstrated potential for use in clinical trials for neurodegenerative therapies.
• Methodology can be adapted for other diseases and tissue types.

Conclusions

• This assay represents a significant advancement in biomarker measurement.
• It has implications for both diagnosis and therapeutic monitoring.
• The technique is poised for clinical translation and broader applications.

Frequently Asked Questions